Prophylactic ureteric stenting in renal transplantation reduces major urological complications; however, morbidity is related to the indwelling duration of a stent. We aimed to determine the optimal duration for stents in this clinical setting. Patients (aged 2-75 years) from six UK hospitals who were undergoing renal transplantation were recruited and randomly assigned to either early stent removal at 5 days (without cystoscopy) or late removal at 6 weeks after transplantation (with cystoscopy). The primary outcome was a composite of stent-related complications defined as pain, visible hematuria, migration, fragmentation, and urinary tract infections (UTIs) within 3 mo of transplantation. Between May 2010 and Nov 2013, we randomly assigned 227 participants, with 205 included in the final analysis of the primary outcome. Stent-related complications were significantly higher in the late versus early stent removal groups (36 of 126 [28.6%] vs. 6 of 79 [7.6%]; p < 0.001). The majority of stent complications consisted of UTIs, with an incidence of 31 of 126 (24.6%) in the late group compared with 6 of 79 (7.6%) in the early group (p = 0.004). We found early stent removal on day 5 significantly reduced stent-related complications and improved quality of life in the first 3 mo after transplantation (ISRCTN09184595).
Prophylactic ureteric stenting in renal transplantation reduces major urological complications; however, morbidity is related to the indwelling duration of a stent. We aimed to determine the optimal duration for stents in this clinical setting. Patients (aged 2-75 years) from six UK hospitals who were undergoing renal transplantation were recruited and randomly assigned to either early stent removal at 5 days (without cystoscopy) or late removal at 6 weeks after transplantation (with cystoscopy). The primary outcome was a composite of stent-related complications defined as pain, visible hematuria, migration, fragmentation, and urinary tract infections (UTIs) within 3 mo of transplantation. Between May 2010 and Nov 2013, we randomly assigned 227 participants, with 205 included in the final analysis of the primary outcome. Stent-related complications were significantly higher in the late versus early stent removal groups (36 of 126 [28.6%] vs. 6 of 79 [7. 6%]; p < 0.001). The majority of stent complications consisted of UTIs, with an incidence of 31 of 126 (24.6%) in the late group compared with 6 of 79 (7.6%) in the early group (p = 0.004). We found early stent removal on day 5 significantly reduced stent-related complications and improved quality of life in the first 3 mo after transplantation (ISRCTN09184595).
Introduction
Kidney transplantation is the optimal management for patients with end-stage kidney disease, improving both quality of life (QoL) and life expectancy. It is recognized that kidney transplantation is associated with complications and morbidity related to both surgery and immunosuppression. Major urological complications (MUCs) of ureteric stenosis or urinary leak that can occur in the early posttransplant period contribute to patient morbidity, graft loss, and mortality. These complications mainly arise from the vesicoureteric anastomosis and occur either as a result of technical failure or ureteric ischemia. It has been shown that placement of a ureteric stent across the vesicoureteric anastomosis at the time of transplantation can significantly reduce these complications (1, 2) . A recent Cochrane review of seven randomized controlled trials (RCTs) and quasi-RCTs of medium to low quality concluded that routine prophylactic stenting for a minimum of 14 days reduces the incidence of MUCs from 0-17.3% (median 7%) to 0-4% (median 1%) (3) . Nevertheless, not all centers routinely stent; some choose to stent selectively when complications may be expected. Stents themselves give rise to potential complications including urinary tract infections (UTIs), visible hematuria, migration, encrustation, and fragmentation as well as potential pain and lower urinary tract symptoms. Stent complications, in particular UTI, not only contribute to patient morbidity but also may compromise allograft function (4) . Consequently, any benefits of prophylactic stenting may be outweighed by their potential complications.
Incidence of stent symptoms and complications appears to be related to the length of time the stents remain in situ (5-7). Timing of stent removal varies between centers, commonly between 2 and 6 weeks after transplantation. The optimal timing for stent removal is currently not known; however, one randomized trial suggested that stents should be removed within 4 weeks to reduce the incidence of infective complications (8) . At our centers, stents are placed for 6 weeks routinely. An internal audit between 2006 and 2008 found stent complications reported in 15-20% of our renal transplant population.
Placement of a ureteric stent during transplantation is a straightforward procedure and provides a scaffold over which the vesicoureteric anastomosis can heal. Removal of the stent requires an additional procedure, incurring additional health care costs and resources. Most stent removal is performed under local anesthesia with flexible cystoscopy, although a general anesthetic and rigid cystoscopy is used routinely in children and is occasionally needed for some adults.
A novel technique of tying the ureteric stent to the urethral catheter was described in 1998 (9) . This allowed the removal of both the stent and the urethral catheter together without recourse to cystoscopy or anesthesia. In the original description of the technique, both the urinary catheter and the attached ureteric stent were removed at a mean of 8 days (range 6-10 days). A retrospective study of this technique in 590 renal transplant recipients, with removal at 10 days (range 8-12 days), found the incidence of urological complications was significantly reduced compared with a nonstented group (10) . This technique enables earlier stent removal without the need for cystoscopy and has the potential to reduce stent-related complications.
We report the results of the randomized Transplant Ureteric Stent Trial (TrUST), designed to determine the benefits of early stent removal in patients managed routinely with prophylactic stenting after renal transplant. We sought to establish whether early ureteric stent removal after renal transplant would decrease stentrelated complications and to determine the effects on MUCs, patient acceptability, and health care costs.
Methods

Study design and participants
In this RCT, patients were recruited from six UK centers. Patients aged 2-75 years needing a renal transplant were included. We excluded those with an increased risk of bleeding and abnormal urinary tract anatomy or function. Patients with planned early use of mTOR (mammalian target of rapamycin) inhibitors were excluded. Abnormal donor urinary tract anatomy and donor stones were also excluded. Full details of all inclusion and exclusion criteria are available in our published protocol (ISRCTN09184595) (11) . Patients gave written informed consent in accordance with good clinical practice. The trial was approved by the London Research Ethics Committee (REC reference 10/H0718/5).
Randomization
An online remote randomization system was provided by the Mental Health and Neurosciences Clinical Trials Unit, King's College London. Recruits were allocated at a 1:1 ratio to either early or late stent-removal groups. Randomization was block-stratified for age (child 2-16 years; adult 17-75 years) with randomly varying block sizes. Trained clinicians and research nurses enrolled participants at each site and were made aware of the allocated group at the time of randomization.
Procedures
An extravesical Lich-Gregoir vesicoureteric anastomosis was performed in all patients over a double-J stent (6F/16 cm polyurethane stent in adults and 4.8-6F/16 cm in children; Cook Medical, Bloomington, IN). A urethral catheter was inserted intraoperatively. In patients randomized to early stent removal, the ureteric stent was attached to the urethral catheter using the string of the stent. An acceptable alternative was to pass a nonabsorbable suture through both the lower end of the stent and the distal drainage eye of the urethral catheter. This was subsequently removed as a single unit on day 5 postoperatively. In the late-removal group, the stent was not attached to the urethral catheter intraoperatively. The catheter was removed on day 5 postoperatively, and the stent was removed with a cystoscope at 6 weeks. Urine samples were routinely collected and tested according to current clinical practice. This included at admission for transplant, prior to urethral catheter removal, at each transplant outpatient clinic, and prior to cystoscopic stent removal. All patients routinely received prophylactic amikacin (7 mg/kg, single dose) at induction and cotrimoxazole (480 mg/day in adults and a weight adjusted dose for pediatric patients) for 6 mo.
Safety outcomes were recorded during clinic visits or hospital admissions and from patient and clinician reports as they happened. Adverse events were collected and recorded by the site local principal investigator. Serious adverse events (SAEs) were reported to the trial office and the chief investigator. Safety events were monitored by the sponsor, the research ethics committee, and the data monitoring committee.
Outcomes
The primary outcome was a composite of complications related to transplant ureteric stent (TUS) defined as pain requiring early removal, visible hematuria requiring catheterization with or without irrigation, migration confirmed on ultrasound or x-ray, fragmentation, and UTIs within 3 mo of transplantation. UTIs were defined as either symptomatic, with midstream urine (MSU) bacterial cultures of >10 2 and pyuria, or asymptomatic, with MSU bacterial cultures of >10 5 and pyuria.
Secondary outcomes assessed and reported were MUCs of vesicoureteric anastomotic leak and stenosis up to 6 mo after transplantation; transient ureteric obstruction, reported as an intermediate urological complication; health status with the EQ-5D and FAIT-U questionnaires, completed at weeks 1 and 6; and patient acceptability using diary cards completed at the time of stent removal. Health care resource use and procedural costs (health economic components) were also assessed and will be reported elsewhere. Other outcomes assessed to better interpret overall study impact included stent symptoms (discomfort, lower urinary tract symptoms, or mild visible hematuria), patient and allograft survival (graft loss was defined as estimated GFR [eGFR] <15 mL/min per 1Á73m 2 return to dialysis, or retransplantation), and renal allograft function (eGFR mL/min per 1.73 m 2 ) at 6 mo.
Statistical analysis
Sample size: Based on audit data collected prior to the study that suggested a 15-20% TUS complication rate with cystoscopic stent removal 6 weeks after transplant (late removal), the trial was powered on the hypothesis that early stent removal would result in a 10-15% reduction in the stent complication rate. Using a v 2 test with 80% power and a two-sided type I error of 0.05, the minimum required sample size was 176 patients, assuming a baseline 20% TUS-related complication rate. The corresponding number was 320 patients, assuming a 15% baseline TUS-related complication rate.
Because there was a degree of uncertainty in the baseline TUS-related complication rate, a preplanned conditional sample size reestimation based on predictive power was performed in May 2013, at which time 105 adult patients and 11 pediatric patients had primary measures available. This inferred that a sample size of 176 adults would provide sufficient statistical power (>80%) to show significant differences as planned between the groups for stent complication rates by the end of the study (see statistical analysis plan for details).
Summary of statistics used: All participants were analyzed according to treatment received (per protocol [PP]) as well as randomization allocation (intention to treat [ITT])
. Outcome data on patients who did not complete 6-mo follow-up were included in the analyses.
For the analysis of the primary end point, Mantel-Haenszel tests were used to stratify across age groups (adult or pediatric) to test for differences between the two study arms. Logistic regressions were also performed for the primary outcome so that an adjusted analysis could be obtained using the following potential covariates in addition to treatment arm: age (pediatric or adult), type of donor (living or deceased), previous recurrent UTIs, dialysis status, diabetes status, and previous transplantation.
Subgroup analyses were performed for the primary outcome using Mantel-Haenszel tests (adjusting for age group and treatment arm) for the following subgroups: donor type (living vs. deceased), surgeon expertise (consultant or other/trainee), and history of previous recurrent UTIs. Subgroup analyses were also performed in which v 2 or Fisher exact tests were used to determine differences between the two study arms for the primary outcome for adults and children separately. Sensitivity analyses were performed in which we removed patients who did not receive their allocated treatment. A sensitivity analysis was also performed to look at the incidence of the individual stent-related complications that composed the composite primary outcome.
For binary secondary outcomes, Mantel-Haenszel tests were used to stratify across age groups. For continuous secondary end points, generalized linear models (both adjusted and unadjusted) were used to test for differences between the two study arms. Nonparametric methods (Wilcoxon tests) were used for nonnormal data to test for treatment effect. SAEs, such as death and graft loss, were reported as secondary outcomes. Other adverse events are listed in full in the supplementary material.
Analyses were done with R version 3.2.2. The statistical analysis plan was approved by the chief investigator and the chair of the data monitoring committee.
Results
Between May 23, 2010, and Nov 30, 2013, 227 participants were randomized into the study (n = 117, late group; n = 110, early group) ( Figure 1 ). There were 15 postrandomization exclusions due to ineligibility, six were lost to follow-up (transferred care to another center), and one did not complete follow-up (died during study); in total, 205 participants were included in the final analysis for the primary outcome. In the early group, 21 patients failed to receive the allocated treatment and were regarded as crossovers into the late group, undergoing late stent removal. Baseline characteristics (Table 1) were similar between the allocation groups. Results below are reported according to treatment received (PP), with both PP and ITT results shown in Table 2 . Of the 205 participants included in the final analysis, 169 completed the week 1 questionnaires and 158 completed the week 6 questionnaires; there was no difference in the proportion completed between groups at week 1 (p = 0.14) but a significant difference at week 6 (p = 0.04), with more completed in early removal group (data not shown). The median duration of the stent in the late group was 42 days (interquartile range [IQR] 38-47 days) compared with 5 days (IQR 5-5 days) in the early group.
The primary outcome measure of stent complications (a composite of pain, UTI, hematuria, fragmentation, and migration) at 3 mo was significantly higher in the late versus early stent removal groups (36 of 126 vs. 6 of 79; p < 0.001) ( 
Allocation
Lost to follow-up for primary end point (n=5) ♦ transferred care to another centre (n=5)
◊ Lost to follow-up according to ITT (n=3) Lost to follow-up for primary end point (n=2)
♦ transferred care to another centre (n=1)
◊ Lost to follow-up according to ITT (n=4) Follow-Up than episodes of pyelonephritis (Table 3 ). In the early group, asymptomatic UTIs were more common (4 of 79, 5.1%) than symptomatic UTIs (2 of 79, 2.5%). The most common organisms were Escherichia coli (45%), Enterococcus faecalis (18%), and Klebsiella (11%). Other stent complications were seen only in the late group: pain in 4 of 126 (3.2%), hematuria in 2 of 126 (1.6%), and migration to the bladder in 3 of 126 (2.4%). There was no incidence of stent fragmentation or encrustation.
Secondary outcome measures included the incidence of MUCs (urine leak and/or stenosis), which was higher in the early group (3 of 80, 3.75%) compared with the late group (1 of 126, 0.8%) but was not statistically significant (p = 0.36). All four patients with MUCs required open surgical revision. There were three patients with transient obstruction in the early group.
Analysis of health status and QoL was assessed using FAIT-U and EQ-5D validated questionnaires. Although there was no difference between the groups at 1 week postoperatively, the FAIT-U total score as well as the physical and functional well-being subscales were significantly better in the early group at 6 weeks (p = 0.012) ( Table 2 and supplementary data). No difference was seen between groups with EQ-5D questionnaires at either time frame. Diary cards were used as a subjective measure of patient acceptability (supplementary data), with no difference reported between the groups for the pain or anxiety of the stent-removal procedure.
SAEs were reported in 20 participants, 13 in the late group and 7 in the early group. There was one death during the study in the early group; this was attributed to a cardiac event. Graft loss was reported in eight patients, three in the late group and five in the early group. None of the SAEs were attributed to trial treatment.
Other outcome measures included stent symptoms, which occurred only in the late-removal group (11 of 126, 8.7%; p = 0.015). There appeared to be a difference in the timing of UTI episodes between groups, with a median of 43 days (IQR 16.50-58.25 days) in late group and 28 days (IQR 18-40 days) in the early group (supplementary data). There was no difference between the groups Data are mean (standard deviation), n (%), or median (interquartile range). DBD, donor after brainstem death; DCD, donor after cardiac death; ITT, intention to treat; PP, per protocol; UTI, urinary tract infection. (Table 2) .
A sensitivity analysis removing all crossovers from the analysis maintained a significant difference in primary outcome measures between groups, with stent complication in 28 of 107 (26.2%) in the late group compared with 6 of 79 (7.6%) in the early group (p = 0.002). In the subgroup analyses, there was no evidence that a prior history of recurrent UTIs (p = 0.63), surgeon experience (p = 0.79), or donor type (p = 0.59) influenced the primary outcome, after adjusting for treatment arm and age group. There was a trend in favor of early stent removal for the primary outcome in all subgroups (Figure 2 ). In the pediatric subgroup, stent complications occurred in 6 of 22 (27.3%) in the late group and 1 of 10 (10%) in the early group (p = 0.387); stent symptoms were reported only in the late group (1 of 22, 4.5%), and there were no MUCs.
Discussion
The results of our trial performed in a routine care setting showed that early ureteric stent removal at 5 days is feasible and reduces the incidence of stent complications compared with cystoscopic stent removal at 6 weeks. This finding was strongly statistically significant when analyzed PP and remained significant when crossovers were removed from the analysis as potential modifiers.
Analysis by ITT showed a 12% (p = 0.055; odds ratio [OR] 2.11, 95% CI 1.04-4.29) reduction in overall stent complications. The power of the study was sufficient to show a clinically useful benefit of early stent removal, with data on primary and secondary outcomes collected from 97% of the cohort. The benefit for the primary outcome with early stent removal was mirrored in the pediatric subgroup, although the study was not powered to show significance in this group.
Our cohort population was diverse but excluded patients with urinary diversion because of different requirements for transplant stent removal. Postrandomization exclusion allowed for problems encountered during organ retrieval, benching, and transplantation. Of the 459 patients screened, 138 (30%) were excluded for ineligibility. The main reason for ineligibility was abnormality of either recipient or donor urinary tract anatomy (35.8%). The study was not blinded because we were unable to conceal the intervention from surgeons or patients; the procedure for stent removal is quite different between groups. A 3-mo end point for stent complications was chosen because previous studies suggest UTIs are most frequent during this period, when immunosuppressant use is maximal. The end point for monitoring MUCs was 6 mo because stenosis can present later in the posttransplantation period.
UTIs were the predominant complication reported and the only stent-related complication reported in the early removal group. The timing of UTI episodes was spread across the 3-mo follow-up period. However, the majority of UTIs in the late group occurred coincidentally with the median duration of stent placement in this group. A prior history of recurrent UTIs was not a predictive variable for posttransplant UTIs or stent complications.
Incidence of stent symptoms was low. Symptoms consisted of discomfort, storage symptoms, or mild hematuria and affected only the late group (8.7%). This finding is consistent with other transplant studies and is much lower than studies in native ureters (80%) (3, 12, 13) . Despite studies reporting lower incidence of urinary symptoms or bother with stents in transplant patients, no previous studies used a validated questionnaire to assess QoL in this population. The Functional Assessment of Chronic Illness Therapy symptom-targeted questionnaire FAIT-U was selected because it focuses on urinary symptoms, and the EQ-5D was used as general health status assessment. At week 1, there was no difference in these measures between groups, perhaps because of the significant morbidity associated with transplantation in both groups at this point. Interestingly, although both groups showed equal general improvement in health status at week 6 (evaluated by EQ-5D), symptom assessment evaluated by FAIT-U was significantly worse (p = 0.01) in the late group, which had stents in situ until this time. There appeared to be significant patient morbidity related to the length of time that the stent was indwelling.
Prophylactic stenting to prevent MUCs in renal transplantation is recommended by current evidence (3 The technique for stent placement in the early group had a learning curve. This is represented by the crossovers from the early to the late group (n = 21), which were mainly due to technical difficulties in attaching the stent to the catheter (n = 15); other reasons were intraoperative nonurological complications during surgery (n = 5) and trial intervention missed by the surgical team (n = 1). The technical difficulties encountered were mainly in locating the catheter through the cystotomy to enable attachment to the stent (n = 11). Adjustments with catheter placement and the volume placed in the catheter balloon helped overcome these difficulties. We did not assess whether the length or size of the cystotomy was increased to overcome difficulties in technique, which could potentially increase risk of MUCs. The strings on the stent need to be placed through the distal drainage eye of the catheter to prevent occlusion of the catheter balloon, rather than around the distal catheter, which occurred on one occasion. Two of the urethral catheter balloons in the pediatric population were fractured during the process of locating it through the cystotomy. This occurred in small 8F urethral catheters and perhaps suggests a limitation for the technique of catheters of ≥10F size.
There were five complications with stent removal in the early group. The urethral catheter and stent fell out early (n = 2), which may have been a result of inadequate volume placement in the catheter balloon, inadvertent damage to the catheter balloon, or a fault with the catheter. The string snapped during removal, requiring cystoscopic removal (n = 1); occlusion of the catheter balloon with the string (n = 1) required percutaneous deflation; and difficulty with catheter removal required cystoscopic removal (n = 1).
A decision to delay stent removal in the early group was made in anuric patients with delayed graft function (DGF) and where a transplant biopsy was needed, to avoid potential complications of bleeding and clot obstruction (n = 2). In recipients of kidneys from standard criteria donors after brainstem death, where DGF is not common (20%), it seems reasonable to use the early stentremoval technique with the current exclusion criteria. However, because it can still be hard to predict DGF, it seems reasonable to delay early stent removal in this group until after a transplant biopsy may be required, at around 1 week after transplant. Recipients of deceased donor kidneys that have a high risk of DGF, such as kidneys from extended criteria donors after brainstem death or from donor after cardiac death, may be advised not to have the stent attached to the catheter but would still benefit from earlier cystoscopic stent removal, perhaps within 4 weeks rather than 6 weeks after transplant (8) .
Conclusion
In our study, early TUS removal on day 5 after transplantation significantly reduced stent complicationsimportantly, UTIs-in the first 3 mo after transplantation. Early stent removal also resulted in significantly improved QoL for patients. We recommend early stent removal for living donor transplants and for recipients of kidneys from standard criteria donors after brainstem death. The pediatric population potentially has the most to gain with early stent removal by removing the need for a general anesthesia procedure, although a limit in terms of patient weight and catheter size may be appropriate.
A nonsignificant increase in the rate of MUCs was seen; however, a study to assess this may not be feasible with the large numbers of patients required. Although the optimal duration remains to be determined and further studies assessing stenting for 1-4 weeks may be required to answer this, early stent removal is beneficial in terms of QoL, stent complications, and use of resources.
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